The White House is preparing an executive order to expand federal research into ibogaine, a psychedelic drug used in some countries to treat PTSD, CBS News reported April 16.
The Trump administration plans to keep ibogaine classified as a Schedule I substance and does not intend to approve it for medical use at this time. President Donald Trump is expected to sign the order as soon as this week, according to the report.
The order is intended to “open the door” to federal funding by supporting studies evaluating ibogaine’s potential use for post-traumatic stress disorder and traumatic brain injuries, particularly among veterans.
Evidence on the drug remains limited. CBS’ report cited a 2023 review of 24 studies including 705 people found reductions in withdrawal symptoms and cravings, but also identified concerns about heart toxicity and risk of death. The report cited at least 27 deaths linked to ibogaine use.
Clinical research is still developing, with only one double-blind, placebo-controlled randomized clinical trial being completed so far. In a separate, smaller study of 30 veterans, no serious cardiac events were reported when ibogaine was administered with intravenous magnesium, though researchers said the data is insufficient to confirm safety.
Several states are funding their own research programs and clinical trials on the drug.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
